Adverse Events in a Breastfed Infant Exposed to Risperidone and Haloperidol

dc.contributor.authorUguz, Faruk
dc.date.accessioned2024-02-23T14:20:56Z
dc.date.available2024-02-23T14:20:56Z
dc.date.issued2019
dc.departmentNEÜen_US
dc.description.abstractSchizophrenia and related psychoses are characterized by high recurrence rates and a serious impact on social functions. Many patients with these conditions, therefore, require prophylactic treatment during the postpartum period. Antipsychotic medication is the main treatment strategy for these disorders. Compared with single use of antipsychotics, data on the safety of combined antipsychotics on the breastfed infants are very limited. The current report presents adverse events in an infant exposed to a combination of risperidone and haloperidol through breast milk.en_US
dc.identifier.doi10.1089/bfm.2019.0093
dc.identifier.endpage684en_US
dc.identifier.issn1556-8253
dc.identifier.issn1556-8342
dc.identifier.issue9en_US
dc.identifier.pmid31135176en_US
dc.identifier.scopus2-s2.0-85074737421en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage683en_US
dc.identifier.urihttps://doi.org/10.1089/bfm.2019.0093
dc.identifier.urihttps://hdl.handle.net/20.500.12452/13352
dc.identifier.volume14en_US
dc.identifier.wosWOS:000469303100001en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherMary Ann Liebert, Incen_US
dc.relation.ispartofBreastfeeding Medicineen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAntipsychoticsen_US
dc.subjectLactationen_US
dc.subjectRisperidoneen_US
dc.subjectHaloperidolen_US
dc.titleAdverse Events in a Breastfed Infant Exposed to Risperidone and Haloperidolen_US
dc.typeArticleen_US

Dosyalar